Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside

17 Apr 2025

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global epidemic, yet effective pharmacological treatments remain limited. Secreted proteins play diverse roles in regulating glucose and lipid metabolism, and their dysregulation is implicated in the development of various metabolic diseases, including MASLD. Therefore, targeting secreted proteins and modulating associated signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblast Growth Factor Research
Share to Liver Disease Diagnosis and Treatment
Share to Metabolism, Diabetes, and Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40243151
DOI: 10.1093/procel/pwaf027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedsidePMID 40243151Read ↗

Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationSemantic proximity Read ↗

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read ↗

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read ↗

The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologiesSemantic proximity Read ↗

The Role of OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASHSemantic proximity Read ↗

Prosaposin: A Multifaceted Protein Orchestrating Biological Processes and DiseasesSemantic proximity Read ↗

Novel genetic insights into the roles of amino acids in metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read ↗

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic SolutionsSemantic proximity Read ↗

Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic TargetSemantic proximity Read ↗

Intestinal bacteria-derived extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: From mechanisms to therapeuticsSemantic proximity Read ↗

Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.